Ï Ç.Ã. åîïìïëïãåßôáé...

Boy ¸ìáèá üôé åßìáé ïñïèåôéêüò ðñéí ôÝóóåñá ÷ñüíéá.

¸ãéíå áðëÜ óå ìßá áðü ôéò åîåôÜóåéò ñïõôßíáò ðïõ Ýêáíá åôçóßùò.
Äåí åß÷á ëüãïõò íá ðåñéìÝíù ôßðïôá ó÷åôéêü. ¹ìïõí ðÜíôá åðéìåëÞò óå èÝìáôá ðñïöýëáîçò. Ðáñ' üë' áõôÜ, ôï áðïôÝëåóìá Þôáí åêåß...

Åß÷á æÞóåé üëç ìïõ ôçí óåîïõáëéêÞ æùÞ õðü ôïí öüâï ôïõ HIV. Êáé ôþñá åß÷å ðñáãìáôïðïéçèåß áõôü ðïõ öïâüìïõí ìéá æùÞ.

ÊÜðïõ åíäüìõ÷á Ýíéùèá íôñïðÞ.
Åß÷á áðïôý÷åé óå ìßá âáóéêÞ áðïóôïëÞ: óôï íá ðñïóôáôÝøù ôï åáõôü ìïõ êáé ôïõò äéêïýò ìïõ áðü áõôÞ ôçí óôåíá÷þñéá.
×þñéá ôçí ñåôóéíéÜ áðü ôïõò ôñßôïõò...

Áðü ôçí Üëëç Ýíéùóá ìéá äéåóôñáììÝíç áíáêïýöéóç.
ÅðéôÝëïõò, ôåëåßùóå ç áãùíßá, Ýãéíå üôé Ýãéíå, äåí ÷ñåéÜæåôáé ðéá íá áíçóõ÷þ êáé íá áã÷þíïìáé.

ÏñãÞ êáé áðüãíùóç Ýíéùóá üôáí Üñ÷éóáí ïé áðïññßøåéò.

Èåùñïýóá ôïí gay ÷þñï åíçìåñùìÝíï óå áõôÜ ôá èÝìáôá, áëëÜ áíôéìåôþðéóá êáôáóôÜóåéò áðü ãñáöéêÝò Ýùò ôåñáôþäåéò.
Åß÷á óõíåéäçôïðïéÞóåé üôé èá Ý÷áíá ìåãÜëï ìÝñïò áõèïñìçôéóìïý áðü ôçí ðñïóùðéêÞ ìïõ æùÞ áëëÜ äåí åß÷á öáíôáóôåß ðüóï ìåãÜëï.
¹ëðéæá íá îåöýãù ìÝóá áðü ôçí äïõëåéÜ ìïõ. Åß÷á Þäç ðñïãñáììáôßóåé íá öýãù óôï åîùôåñéêü êáé íá äïõëÝøù óå ìßá êáôáóêåõáóôéêÞ ðïëõåèíéêÞ óôïí Áñáâéêü êüëðï.
ÎáöíéêÜ ìå åíçìåñþóáíå áðü ôï íïóïêïìåßï ãéá ôá áõóôçñÜ éáôñéêÜ ôåóô ôá ïðïßá åöáñìüæïíôáé åêåß êáé ôá ïðïßá èá ìå Ýêñéíáí áðïññéðôÝï. Åêåß Ý÷áóá ôïí êüóìï êÜôù áðü ôá ðüäéá ìïõ ãéá ðñþôç öïñÜ.

Óõí ôïéò Üëëïéò êÜðïéïé "ößëïé" äåí óôÜèçêáí óôï ýøïò ôùí ðåñéóôÜóåùí.
¢ñ÷éóá íá âõèßæïìáé óôçí êáôÜèëéøç.
ÐéÜíïíôáò ôïí ôáýñï áðü ôá êÝñáôá üìùò âñßóêåé êáíåßò ôï óçìåßï íá êÜíåé åðáíåêêßíçóç.

ÓõíÝ÷éóá ìå ôï áíôéêåßìåíü ìïõ óôçí ÅëëÜäá.
ÎåóêÜñôéóá ôçí æùÞ ìïõ áðü ÷éëßùí åéäþí óáâïýñåò êáé Ýêáíá ÷þñï ãéá ôá ðñÜãìáôá ðïõ åßíáé ðñáãìáôéêÜ óçìáíôéêÜ ãéá ìÝíá.

¢ñ÷éóá ìáèÞìáôá æùãñáöéêÞò ðïõ ðÜíôá áãáðïýóá. Ïé êáèçãçôÝò ìïõ ìå ðáñüôñõíáí íá äþóù ãéá Êáëþí Ôå÷íþí, êÜôé ðïõ ïíåéñåõüìïõí áðü ðáéäß.
Äåí åß÷á áéóèáíèåß ðïôÝ óôçí æùÞ ìïõ ðéï ÷áñïýìåíïò Þ ðéï óßãïõñïò ãéá êÜðïéá åðéëïãÞ ìïõ.

Êáé ï Ýñùôáò áðëÜ Þñèå.
Êáé íá Þèåëá äåí èá ìðïñïýóá íá ôïí óôáìáôÞóù...




... 'Aëëåò éóôïñßåò ...



Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò